The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MRVI | -56.73% | N/A | N/A | -89% |
| S&P | +14.5% | +93.32% | +14.09% | +88% |
Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The Protein Detection segment is engaged in manufacturing and selling labeling and visual detection reagents to scientific research customers for their tissue-based protein detection and characterization needs. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
These stocks are also cheap buys that are down more than 60% from their highs.
These two companies are facing short-term issues that are likely to give way to long-term success.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $47.40M | -35.4% |
| Gross Profit | $7.17M | -74.6% |
| Gross Margin | 15.12% | -23.4% |
| Market Cap | $346.98M | -63.5% |
| Market Cap / Employee | $0.61M | 0.0% |
| Employees | 570 | -12.3% |
| Net Income | -$69.84M | -381.9% |
| EBITDA | -$13.08M | -578.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $269.91M | -52.9% |
| Accounts Receivable | $27.88M | -27.9% |
| Inventory | 46.7 | -5.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $356.84M | -35.0% |
| Short Term Debt | $14.24M | 7.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -16.61% | -9.5% |
| Return On Invested Capital | 4.19% | -3.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13.14M | -266.7% |
| Operating Free Cash Flow | -$10.27M | -158.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.41 | 2.24 | 0.96 | 1.15 | -50.10% |
| Price to Sales | 4.25 | 2.98 | 1.31 | 1.61 | -53.87% |
| Price to Tangible Book Value | -41.27 | -27.07 | -10.62 | -5.90 | -19.62% |
| Price to Free Cash Flow TTM | 14.27 | - | |||
| Enterprise Value to EBITDA | 816.96 | -88.68 | -31.31 | -49.76 | -110.46% |
| Free Cash Flow Yield | 7.0% | - | |||
| Return on Equity | -52.0% | -39.0% | -45.8% | -55.4% | 100.85% |
| Total Debt | $561.08M | $376.69M | $326.65M | $371.08M | -33.96% |
MRVI earnings call for the period ending December 31, 2024.
MRVI earnings call for the period ending September 30, 2024.
MRVI earnings call for the period ending June 30, 2024.
MRVI earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
